Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

First, we were thrilled to receive an optimal label in the United States with the recent FDA approval of VYVGART Hytrulo pre ... Now each patient can dose the drug the way it should be dosed ...

“We remain committed to delivering meaningful outcomes with VYVGART by setting a new benchmark for sustained ... ARGX-121, a first-in-class molecule targeting IgA; ARGX-109, targeting IL-6, which ...

The FDA has approved five other drugs for gMG in recent years. Argenx’s efgartigimod alfa (Vyvgart) and UCB’s ... Biohaven is developing small-molecule extracellular protein degraders that ...

The focus of Priovant is brepocitinib, an orally administered small molecule drug that inhibits both Tyrosine ... annual net price equivalent to Vyvgart's MG pricing of about $225,000 suggests ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

The US Food and Drug Administration (FDA) has approved a prefilled syringe for self-injection of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) in the treatment of adults with ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...

The drug is already approved as an under-the-skin injection, branded as Vyvgart Hytrulo, and in intravenous form to treat gMG and CIDP. Vyvgart Hytrulo uses the active ingredient efgartigimod and ...